Ovarian Cancer

Dr. Michael Birrer, from Massaschusetts General Hospital Cancer Center, Discusses Recurrent Ovarian Cancer Treatment

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Subfertile women who undergo ovarian stimulation for in vitro fertilization have an increased risk of ovarian malignancies.

Bevacizumab (Avastin) improved progression-free survival (PFS) in patients with ovarian cancer but was not shown to affect overall survival (OS), according to a new study...

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.

Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Long-term use of talc-based powder significantly increased the risk of invasive ovarian cancer in a large case-control study

More often than not, ovarian cancer is diagnosed at an advanced stage

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

The goal of personalized medicine remains in its infancy as oncologists strive to determine treatments specific to a patient's tumor characteristics

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

Dr. Markman Discusses the Olaparib Phase II Trial

Dr. Pecora on Ovarian Cancer PARP Inhibitor for Ovarian Cancer

Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments

Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial